- Home
- BTAI vs CODX Comparison
BTAI vs CODX Comparison
Compare BTAI & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- CODX
- Stock Information
- Founded
- BTAI 2017
- CODX 2013
- Country
- BTAI United States
- CODX United States
- Employees
- BTAI N/A
- CODX N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- BTAI Health Care
- CODX Health Care
- Exchange
- BTAI Nasdaq
- CODX Nasdaq
- Market Cap
- BTAI 8.3M
- CODX 9.8M
- IPO Year
- BTAI 2018
- CODX 2017
- Fundamental
- Price
- BTAI $1.84
- CODX $0.28
- Analyst Decision
- BTAI Buy
- CODX Buy
- Analyst Count
- BTAI 5
- CODX 2
- Target Price
- BTAI $34.60
- CODX $5.50
- AVG Volume (30 Days)
- BTAI 294.8K
- CODX 491.4K
- Earning Date
- BTAI 08-05-2025
- CODX 08-07-2025
- Dividend Yield
- BTAI N/A
- CODX N/A
- EPS Growth
- BTAI N/A
- CODX N/A
- EPS
- BTAI N/A
- CODX N/A
- Revenue
- BTAI $1,852,000.00
- CODX $3,497,583.00
- Revenue This Year
- BTAI $5.03
- CODX N/A
- Revenue Next Year
- BTAI $291.01
- CODX $42.11
- P/E Ratio
- BTAI N/A
- CODX N/A
- Revenue Growth
- BTAI 5.47
- CODX N/A
- 52 Week Low
- BTAI $1.17
- CODX $0.23
- 52 Week High
- BTAI $23.04
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- BTAI 62.90
- CODX 43.19
- Support Level
- BTAI $1.59
- CODX $0.26
- Resistance Level
- BTAI $2.22
- CODX $0.29
- Average True Range (ATR)
- BTAI 0.21
- CODX 0.02
- MACD
- BTAI 0.04
- CODX 0.00
- Stochastic Oscillator
- BTAI 75.00
- CODX 26.83
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.